Clinical trial · Interventional
Feasibility Study Into Adjustment of the Radiation Beam to Account for Prostate Motion During Radiotherapy.
Phase I Feasibility Study of Prostate Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator Adaptation and Radiofrequency Tracking (Calypso)
NCT02033343CI-TRIAL-00052251CALYPSOcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to monitor movement of the prostate during radiotherapy and adjust the radiation beam to account for any motion seen. This will increase the radiation dose to the prostate and decrease the dose to the rectum and bladder.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Prostate cancer radiotherapy using real-time tracking | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Real-time tracking & beam adjustment
- description
- Prostate cancer radiotherapy using real-time tracking
- interventionNames
- Radiation: Prostate cancer radiotherapy using real-time tracking
Primary outcomes (1)
- measure
- Percentage of fractions being successfully delivered with Calypso-guided tracking.
- timeFrame
- 2 years
- description
- The primary endpoint of this Pilot study is to evaluate the feasibility of implementing realtime adaptive radiotherapy using DMLC. This will be assessed as greater than 95% of fractions being successfully delivered (no equipment failures and tracking MLC follows beacons) with Calypso-guided tracking.
Secondary outcomes (5)
- measure
- Improvement in overall beam-target geometric alignment.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 35 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Patients undergoing external beam radiotherapy at Northern Sydney Cancer Centre * Histologically proven prostate adenocarcinoma * Prostate Specific Antigen (PSA) obtained within 3 months prior to enrolment. * Patient must be able to have Varian Calypso beacons placed in the prostate (if on anticoagulants, must be cleared by Local Medical Officer or cardiologist). * ECOG performance status 0-2 * Ability to understand and the willingness to sign a written informed consent document. * Body habitus enabling Calypso tracking (as per Calypso Determining a Patient's Localisation Designation \& Orientation before implantation) * Prostate dimension that allows leaf span with tracking margin of ±8mm Exclusion Criteria: * Previous pelvic radiotherapy * Prior total prostatectomy * Pacemaker * Implantable defibrillator * Insulin infusion pump * Hip prosthesis * Unwilling or unable to give informed consent * Unwilling or unable to complete quality of life questionnaires.
References
Publications (3)
- BACKGROUNDColvill E, Booth JT, O'Brien RT, Eade TN, Kneebone AB, Poulsen PR, Keall PJ. Multileaf Collimator Tracking Improves Dose Delivery for Prostate Cancer Radiation Therapy: Results of the First Clinical Trial. Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):1141-1147. doi: 10.1016/j.ijrobp.2015.04.024. Epub 2015 Apr 17. PMID 26194684
- RESULTKeall PJ, Colvill E, O'Brien R, Ng JA, Poulsen PR, Eade T, Kneebone A, Booth JT. The first clinical implementation of electromagnetic transponder-guided MLC tracking. Med Phys. 2014 Feb;41(2):020702. doi: 10.1118/1.4862509. PMID 24506591
- RESULTColvill E, Poulsen PR, Booth JT, O'Brien RT, Ng JA, Keall PJ. DMLC tracking and gating can improve dose coverage for prostate VMAT. Med Phys. 2014 Sep;41(9):091705. doi: 10.1118/1.4892605. PMID 25186380